Abstract:Yes-associated protein (YAP), a potent oncogene and a key player in the Hippo tumor suppression pathway, has long been considered challenging to target due to its partially intrinsically disordered nature. However, recent advancements in High-throughput Screening (HTS) have yielded a breakthrough, as several YAP binders have been identified, igniting new possibilities in the quest to combat YAP-driven malignancies. Building upon this progress, a novel approach utilizing Proteolysis-Targeting Chimera (PROTAC) technology was employed to design and synthesize a series of YAP degraders. Here, our degraders were created by linking NSC682769, a previously reported YAP binder, with either VHL ligand 2 or pomalidomide using various linkers of different lengths and types. Among these degraders, YZ-6 emerges as the most promising, inducing rapid and sustained YAP degradation via promoting its ubiquitination-proteasome-dependent proteolysis. This process effectively suppressed YAP/TEAD-led transcription in both YAP-dependent NCI-H226 and Huh7 cancer cell lines. In addition to its degradation capabilities, YZ-6 also exhibited antiproliferative activity in both cell lines. Importantly, YZ-6 efficiently suppressed tumor development in the Huh7 xenograft mouse model, accompanied by a remarkable decrease in YAP levels, without adverse effects on the mice. These findings highlight the potential of PROTAC-mediated degradation as a viable strategy for reducing oncogenic YAP levels and attenuating downstream signaling in cancer cells. Moreover, the development of PROTACs based on NSC672869 holds promise for treating YAP-driven malignancies, opening new avenues for cancer therapy. Citation Format: Chen Zhou, Chunbao Sun, Liya Pi, Chenglong Li. Exploration degradation of intrinsically disordered protein YAP induced by PROTACs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4513.

Bumped pomalidomide-based PROTACs

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects

Potent and Preferential Degradation of CDK6 Via Proteolysis Targeting Chimera Degraders

Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy

Precise Modulation of Protein Degradation by Smart PROTACs

Hijacking the MDM2 E3 Ligase with novel BRD4-Targeting PROTACs in Pancreatic Cancer Cells

Inducible Degradation of Oncogenic Nucleolin Using an Aptamer-Based PROTAC

Discovery of Alkenyl Oxindole as a Novel PROTAC Moiety for Targeted Protein Degradation via CRL4 Recruitment

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway

Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7

Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment

Light-induced Control of Protein Destruction by Opto-Protac.

First small-molecule PROTACs for G protein-coupled receptors: inducing 1A-adrenergic receptor degradation

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase‐based Partial PROTAC Library

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy

Discovery of novel penetrating peptides able to target human leukemia and lymphoma for enhanced PROTAC delivery

A Degron Blocking Strategy Towards Improved CRL4CRBN Recruiting PROTAC Selectivity

Abstract 4513: Exploration degradation of intrinsically disordered protein YAP induced by PROTACs